Gildeuretinol Halts Stargardt Progression in Interim TEASE-3 Results
Additional TEASE-3 participants who completed 24 months of gildeuretinol therapy reported no progression in Stargardt disease, including stable visual acuity.
Related Articles
Is that a bird’s nest or base station? Why not both
Everything in Australia is deadly, in this case giant eagles guarding eggs in places wireless broadband techs need to reach
Team Building Through Positive Psychology Principles in the Pediatric Cardiac Operating Room
HEALTH CARE WORKFORCE INNOVATION THEME ISSUE: Cincinnati Children’s Hospital Medical Center improved morale and reduced turnover in its cardiothoracic surgical unit with a focused, long-term…
Revolutionizing Startups: Dassault Systèmes’ 3DEXPERIENCE Lab Empowering Entrepreneurs with AI and Sustainability Initiatives
Podcast Episode · What’s Up with Tech? · 01/09/2025 · 9m
Human metapneumovirus (hMPV) infection
When autocomplete results are available use up and down arrows to review and enter to select. Human metapneumovirus (hMPV) is one of the viruses that…
Shaping Tomorrow’s Products with Cutting-Edge Design Tools
Podcast Episode · What’s Up with Tech? · 01/09/2025 · 5m
Peter Fenwick, Leading Expert on Near-Death Experiences, Dies at 89
He was a neuropsychiatrist who was studying consciousness when a patient explained what had happened to him, and he realized the phenomenon was real.
Peter Fenwick, Leading Expert on Near-Death Experiences, Dies at 89
He was a neuropsychiatrist who was studying consciousness when a patient explained what had happened to him, and he realized the phenomenon was real.
Social Capital and Cultural Health Capital in Primary Care: The Case of Group Medical Visits
This article focuses on an empirical setting that upends the clinician–patient dyadic norm: group medical visits (GMVs), in which multiple patients gather in the same…
Outlier UK’s least-bad fix is via a weak currency
Britain’s latest debt turmoil contains the seeds of its own solution. The recent surge in bond yields exposed the UK’s reliance on foreign capital. A…
Inside RFK Jr.’s financials: Biotech investment, health care consulting, ‘author introductions’
Documents show Robert F. Kennedy Jr. invested in biotech companies and consulted on health care — interests he might have to forgo as health secretary.
